Results 31 to 40 of about 36,944 (259)
WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma
Genes & Development, 2021 In this study, Driskill et al. studied whether the TAZ-CAMTA1 gene fusion is a driver of epithelioid hemangioendothelioma (EHE), a poorly understood and devastating vascular cancer.
Jordan H. Driskill +7 more
semanticscholar +1 more source
Clinical Cancer Research, 2022 Purpose: A consistent genetic alteration in vascular cancer epithelioid hemangioendothelioma (EHE) is the t(1;3)(p36;q25) chromosomal translocation, which generates a WWTR1(TAZ)-CAMTA1 (TC) fusion gene. TC is a transcriptional coactivator that drives EHE.
Shuang Ma +9 more
semanticscholar +1 more source
World Journal of Clinical Cases, 2022 BACKGROUND Hepatic epithelioid hemangioendothelioma (HEHE) is a rare hepatic vascular tumor with unpredictable malignant potential. The etiology, characteristics, diagnosis, treatment, and prognosis of HEHE are not well-understood, and large-scale ...
Man Zhao, Fei Yin
semanticscholar +1 more source
MRI appearances of hepatic epithelioid hemangioendothelioma: a retrospective study of 57 patients
Insights into Imaging, 2022 Background Hepatic epithelioid hemangioendothelioma (HEH) is extremely rare and the MRI features have never been investigated in a large group of patients. Methods A retrospective study was designed to review the MRI images of HEH patients.
Xiaolei Liu +7 more
semanticscholar +1 more source
Unraveling the Biology of Epithelioid Hemangioendothelioma, a TAZ–CAMTA1 Fusion Driven Sarcoma
Cancers, 2022 Simple Summary Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer that involves a gain-of-function gene fusion involving TAZ, a transcriptional coactivator, and one of two end effectors of the Hippo pathway. Although the activity of TAZ and/
C. Seavey, A. Pobbati, B. Rubin
semanticscholar +1 more source
Journal of Surgical Oncology, 2022 Hepatic epithelioid hemangioendothelioma (HEH) is a rare vascular tumor of unknown etiology and unpredictable natural history. To date, no large‐scale studies have been published evaluating this disease due to its rare occurrence.
P. Ajay +10 more
semanticscholar +1 more source
The challenging surgical management of hepatic epithelioid hemangioendothelioma: a narrative review.
Chinese Clinical Oncology, 2022 BACKGROUND AND OBJECTIVE Hepatic epithelioid hemangioendothelioma (HEHE) is an uncommon vascular endothelial cell cancer involving the hepatic tissue with full malignant potential.
F. Giovanardi +4 more
semanticscholar +1 more source
A Case Report of Prostatic and Peritoneal Hemangioendothelioma
Journal of Urological Surgery, 2018 Epithelioid hemangioendothelioma is a rare endothelial neoplasm that is uncommonly described in the urinary system. To date, only one case has been described as originating from the prostate.
Michael Lao +3 more
doaj +1 more source
Pseudomyogenic Hemangioendothelioma (Epithelioid Sarcoma-Like Hemangioendothelioma) [PDF]
Archives of Pathology & Laboratory Medicine, 2019 Pseudomyogenic hemangioendothelioma (PMH) is a rare vascular tumor that presents more frequently in young adults and has a male predominance. It is usually located in the superficial or deep soft tissues of the extremities, but concurrent bone involvement can be present.
Gustavo A, Caballero, Pablo D, Roitman
openaire +2 more sources
Frontiers in Oncology, 2022 Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originated from vascular endothelial cells, with unpredictable malignancy. No standard treatment has been established yet. Although surgical resection and liver transplantation have been
Xiaolei Liu +6 more
semanticscholar +1 more source